×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
QGEN – qiagen n.v. common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
QGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/15
01:38 am
qgen
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation [Yahoo! Finance]
Low
Report
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation [Yahoo! Finance]
4/15
01:30 am
qgen
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
Low
Report
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
4/8
11:22 am
qgen
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Medium
Report
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
4/6
02:28 pm
qgen
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
Medium
Report
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
4/4
09:13 am
qgen
Qiagen (NYSE: QGEN) was downgraded by analysts at Redburn Atlantic from a "buy" rating to a "neutral" rating.
Medium
Report
Qiagen (NYSE: QGEN) was downgraded by analysts at Redburn Atlantic from a "buy" rating to a "neutral" rating.
4/1
01:30 am
qgen
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
Low
Report
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
3/31
06:00 am
qgen
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
Low
Report
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
3/19
07:07 am
qgen
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH [Yahoo! Finance]
Low
Report
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/9
06:00 am
qgen
Form 6-K QIAGEN N.V. For: Apr 30
Medium
Report
Form 6-K QIAGEN N.V. For: Apr 30
3/31
06:01 am
qgen
Form 20-F QIAGEN N.V. For: Dec 31
Low
Report
Form 20-F QIAGEN N.V. For: Dec 31
2/7
06:00 am
qgen
Form 6-K QIAGEN N.V. For: Dec 31
Low
Report
Form 6-K QIAGEN N.V. For: Dec 31
2/6
09:38 am
qgen
Form SCHEDULE 13G QIAGEN N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G QIAGEN N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
1/16
05:00 pm
qgen
Form 6-K QIAGEN N.V. For: Jan 31
Low
Report
Form 6-K QIAGEN N.V. For: Jan 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/3
European shares rise 2% on stimulus hopes [Reuters]
16.8%
12/26 Qiagen NV (NYSE: QGEN) had its "underperform" rating re-affirmed by analysts at Bank of America Corp. They now have a $28.00 price target on the stock. 11.0%
11/15 QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives 8.5%
11/13 Qiagen up 7% on rumored Thermo Fisher interest [Seeking Alpha] 6.2%
10/9 Qiagen NV (NYSE: QGEN) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating. 5.4%
1/8 Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio 5.3%
2/4 Q4/2019 12/31/2019 EPS 0.480 ZacksConsensus 0.440 ActVsEst 0.040 - Beat 5.1%
11/6 QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting 4.2%
2/26 QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2 3.9%
3/31 QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus 2.7%
12/26 Qiagen NV (NYSE: QGEN) had its "underperform" rating re-affirmed by analysts at Bank of America Corp. They now have a $28.00 price target on the stock. 11.0%
11/15 QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives 8.5%
11/13 Qiagen up 7% on rumored Thermo Fisher interest [Seeking Alpha] 6.2%
10/9 Qiagen NV (NYSE: QGEN) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating. 5.4%
1/8 Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio 5.3%
2/4 Q4/2019 12/31/2019 EPS 0.480 ZacksConsensus 0.440 ActVsEst 0.040 - Beat 5.1%
11/6 QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting 4.2%
2/26 QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2 3.9%
3/31 QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus 2.7%
TOP News Decliners
10/7
QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
-18.0%
5/6 Q1/2019 3/31/2019 EPS 0.270 ZacksConsensus 0.260 ActVsEst 0.010 - Beat -5.2%
3/11 Is This The Next Major Roadblock To The White House's Coronavirus Response? [zero hedge] -4.2%
7/24 Q2/2019 6/30/2019 EPS 0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.1%
11/18 Europe markets mostly higher as US-China trade talks dominate sentiment; Qiagen up 13% [CNBC] -3.2%
9/30 QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays and Analyses for Life Science Research -3.1%
2/5 Qiagen NV (NYSE: QGEN) had its "neutral" rating re-affirmed by analysts at Barclays PLC. -2.4%
3/18 Severe shortages of swabs and other supplies hamper testing [CNN] -2.2%
1/20 UPDATE 1-European shares dip as investors eye PMI data, ECB meeting [Reuters (UK)] -2.1%
8/20 Qiagen NV (NYSE: QGEN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -1.9%
5/6 Q1/2019 3/31/2019 EPS 0.270 ZacksConsensus 0.260 ActVsEst 0.010 - Beat -5.2%
3/11 Is This The Next Major Roadblock To The White House's Coronavirus Response? [zero hedge] -4.2%
7/24 Q2/2019 6/30/2019 EPS 0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.1%
11/18 Europe markets mostly higher as US-China trade talks dominate sentiment; Qiagen up 13% [CNBC] -3.2%
9/30 QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays and Analyses for Life Science Research -3.1%
2/5 Qiagen NV (NYSE: QGEN) had its "neutral" rating re-affirmed by analysts at Barclays PLC. -2.4%
3/18 Severe shortages of swabs and other supplies hamper testing [CNN] -2.2%
1/20 UPDATE 1-European shares dip as investors eye PMI data, ECB meeting [Reuters (UK)] -2.1%
8/20 Qiagen NV (NYSE: QGEN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: